In vitro effects on biofilm viability and antibacterial and antiadherent activities of silymarin

Folia Microbiologica

Volumn 60, Issue 4, 2015, Pages 351-356

  Evren, Ebru ^a   Yurtcu, Erkan ^a  

^a BASKENT UNIVERSITY   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIA (MICROORGANISMS); NEGIBACTERIA; POSIBACTERIA; SILYBUM MARIANUM;

ANTIINFECTIVE AGENT; SILYMARIN;

BACTERIUM ADHERENCE; BIOFILM; CHEMISTRY; DRUG EFFECTS; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE BACTERIUM; ISOLATION AND PURIFICATION; METABOLISM; MICROBIAL SENSITIVITY TEST; MICROBIAL VIABILITY; PHYSIOLOGY; SILYBUM MARIANUM;

ANTI-BACTERIAL AGENTS; BACTERIAL ADHESION; BIOFILMS; GRAM-NEGATIVE BACTERIA; GRAM-POSITIVE BACTERIA; MICROBIAL SENSITIVITY TESTS; MICROBIAL VIABILITY; MILK THISTLE; SILYMARIN;

EID: 84929950842     PISSN: 00155632     EISSN: 18749356     Source Type: Journal    
DOI: 10.1007/s12223-015-0399-6     Document Type: Article

References (44)

1. Abenavoli L, Capasso R, Milic N, Capasso F (2010) Milk thistle in liver diseases: past, present, future. Phytother Res 24:1423–1432
2. Agarwal C, Singh RP, Dhanalakshmi S, Tyagi AK, Tecklenburg M, Sclafani RA, Agarwal R (2003) Silibinin upregulates the expression of cyclin-dependent kinase inhibitors and causes cell cycle arrest and apoptosis in human colon carcinoma HT-29 cells. Oncogene 22:271–82
3. Alviano DS, Barreto AL, Dias Fde A, Rodrigues Ide A, Rosa Mdo S, Alviano CS, Soares RM (2012) Conventional therapy and promising plant-derived compounds against trypanosomatid parasites. Front Microbiol 6(3):283
4. Bakkali F, Averbeck S, Averbeck D, Idaomar M (2008) Biological effects of essential oils—a review. Food Chem Toxicol 46(2):446–75
5. Baylan O (2010) Fosfomycin: past, present and future. Mikrobiyol Bul 44:311–321
6. Bibi Y, Nisa S, Chaudhary FM, Zia M (2011) Antibacterial activity of some selected medicinal plants of Pakistan. BMC Complement Altern Med 11:52
7. Bjarnsholt T (2013) The role of bacterial biofilms in chronic infections. APMIS Suppl 136:1–51. doi:10.1111/apm.12099
8. Ceri H, Olson ME, Stremick C, Read RR, Morck D, Buret A (1999) The Calgary biofilm device: new technology for rapid determination of antibiotic susceptibilities of bacterial biofilms. J Clin Microbiol 37(6):1771–6
9. Christensen GD, Simpson WA, Younger JJ, Baddour LM, Barrett FF, Melton DM, Beachey EH (1985) Adherence of coagulase negative staphylococci to plastic tissue cultures: a quantitative model for the adherence of staphylococci to medical devices. J Clin Microbiol 22:996–1006
10. Clinical and Laboratory Standards Institute (CLSI) (2012) Performance standards for antimicrobial susceptibility testing; twenty-second informational supplement M100-S22. CLSI, Wayne
11. Coenye T, Nelis HJ (2010) In vitro and in vivo model systems to study microbial biofilm formation. J Microbiol Methods 83:89–105
12. Cushnie TP, Lamb AJ (2005) Antimicrobial activity of flavonoids. Int J Antimicrob Agents 26(5):343–56
13. Donlan RM (2001) Biofilm formation: a clinically relevant microbiological process. Healthcare Epidemiology CID 33:1387–1392
14. Donlan RM (2011) Biofilm elimination on intravascular catheters: important considerations for the infectious disease practitioner. Healthcare Epidemiology CID 52:1039–1045
15. Edwards-Jones V (2013) Alternative antimicrobial approaches to fighting multi-drug resistant infections. In: Rai M, Kon K (eds) Frightening multidrug resistance with herbal extracts, essential oils and their components. Elsevier, USA, pp 1–9
16. Flaig TW, Gustafson DL, Su LJ, Zirrolli JA, Crighton F, Harrison GS, Pierson AS, Agarwal R, Glodé LM (2007) A phase I and pharmacokinetic study of silybin-phytosome in prostate cancer patients. Invest New Drugs 25:139–146
17. Gharagozloo M, Javid EN, Rezaei A, Mousavizadeh K (2013) Silymarin inhibits cell cycle progression and mTOR activity in activated human T cells: therapeutic implications for autoimmune diseases. Basic Clin Pharmacol Toxicol 112(4):251–6
18. Ghosh A, Ghosh T, Jain S (2010) Silymarin-a review on the pharmacodynamics and bioavailability enhancement approaches. J Pharm Sci Tech 2:348–355
19. Gordon A, Hobbs DA, Bowden DS, Bailey MJ, Mitchell J, Francis AJ, Roberts SK (2006) Effects of Silybum marianum on serum hepatitis C virus RNA, alanine aminotransferase levels and well-being in patients with chronic hepatitis C. J Gastroenterol Hepatol 21:275–280
20. Hall MR, McGillicuddy E, Kaplan LJ (2014) Biofilm: basic principles, pathophysiology, and implications for clinicians. Surg Infect (Larchmt) 15(1):1–7
21. Hassan A, Usman J, Kaleem F, Omair M, Khalid A, Iqbal M (2011) Evaluation of different detection methods of biofilm formation in the clinical isolates. Braz J Infect Dis 15:305–311
22. Høiby N, Bjarnsholt T, Moser C, Bassi GL, Coenye T, Donelli G, Hall-Stoodley L, Holá V, Imbert C, Kirketerp-Møller K, Lebeaux D, Oliver A, Ullmann AJ, Williams C (2015) ESCMID guideline for the diagnosis and treatment of biofilm infections 2014. Clin Microbiol Infect. doi:10.1016/j.cmi.2014.10.024
23. http://www.cancer.gov/cancertopics/pdq/cam/milkthistle/HealthProfessional/page1 access: 07/10/2014
24. http://www.sigmaaldrich.com/catalog/analytical/supelco/g005739?lang=en®ion=TR 02/25/2015
25. Ji-Lu S, Shao-Kang Z, Jing-Yu C, Bei-Zhong H (2012) Efficacy of acidic and basic electrolyzed water in eradicating Staphylococcus aureus biofilm. Can J Microbiol 58:448–454
26. Kang HK, Kim HY, Cha JD (2011) Synergistic effects between silibinin and antibiotics on methicillin-resistant Staphylococcus aureus isolated from clinical specimens. Biothecnol J 13:397–408
27. Lahlah ZF, Meziani M, Maza A (2012) Silymarin natural antimicrobial agent extracted from Silybum marianum. Journal Academia 2:164–169
28. Lee DG, Kim HK, Park Y, Park SC, Woo ER, Jeong HG, Hahm KS (2003) Gram positive bacteria specific properties of silybin derived from Silbum marianum. Arch Pharm Res 26:597–600
29. Lee YS, Jang KS, Cha JD (2012) Synergistic antibacterial effect between silibinin and antibiotics in oral bacteria. J Biomed Biotechnol 2012:618081. doi:10.1155/2012/618081
30. Lucey MR, Mathurin P, Morgan TR (2009) Alcoholic hepatitis. N Engl J Med 360:2758–69
31. Polyak SJ, Morishima C, Lohmann V, Pal S, Lee DY, Liu Y, Graf TN, Oberlies NH (2010) Identification of hepatoprotective flavonolignans from silymarin. Proc Natl Acad Sci U S A 107(13):5995–9
32. Polyak SJ, Ferenci P, Pawlotsky JM (2013) Hepatoprotective and antiviral functions of silymarin components in hepatitis C virus infection. Hepatology 57:1262–1271
33. Post-White J, Ladas EJ, Kelly KM (2007) Advances in the use of milk thistle (Silybum marianum). Integr Cancer Ther 6:104–109
34. Ramasamy K, Agarwal R (2008) Multitargeted therapy of cancer by silymarin. Cancer Lett 8:352–362
35. Sanchez-Sampedro A, Kim HK, Choi YH, Verpoorte R, Corchete P (2007) Metabolomic alterations in elicitor treated Silybum marianum suspension cultures monitored by nuclear magnetic resonance spectroscopy. J Biotechnol 130:133–142
36. Simánek V, Kren V, Ulrichová J, Vicar J, Cvak L (2000) Silymarin: what is in the name…? An appeal for a change of editorial policy. Hepatology 32(2):442–4
37. Stepanovic S, Vukovic D, Savic B, Svabic-Vlahovic M (2000) A modified microtiter-plate test for quantification of staphylococcal biofilm formation. J Microbiol Methods 40(2):175–9
38. Stoddart MJ (2011) Cell viability assays: introduction. Methods Mol Biol 740:1–6
39. Tamayo C, Diamond S (2007) Review of clinical trials evaluating safety and efficacy of milk thistle (Silybum marianum [L.]gaertn.). Integr Cancer Ther 6:146–157
40. Wagoner J, Negash A, Kane OJ, Martinez LE, Nahmias Y, Bourne N, Owen DM, Grove J, Brimacombe C, McKeating JA, Pécheur EI, Graf TN, Oberlies NH, Lohmann V, Cao F, Tavis JE, Polyak SJ (2010) Multiple effects of silymarin on the hepatitis C virus lifecycle. Hepatology 51:1912–1921
41. Walencka E, Sadowska B, Rozalska S, Hryniewicz W, Rózalska B (2005) Lysostaphin as a potential therapeutic agent for staphylococcal biofilm eradication. Pol J Microbiol 54(3):191–200
42. Walencka E, Sadowska B, Rozalska S, Hryniewicz W, Rozalska B (2006) Staphylococcus aureus biofilm as a target for single or repeated doses of oxacillin, vancomycin, linezolid and/or lysostaphin. Folia Microbiol 51:381–386
43. Wei F, Liu SK, Liu XY, Li ZJ, Li B, Zhou YL, Zhang HY, Li YW (2013) Meta-analysis: silymarin and its combination therapy for the treatment of chronic hepatitis B. Eur J Clin Microbiol Infect Dis 32:657–669
44. Wen Z, Dumas TE, Schrieber SJ, Hawke RL, Fried MW, Smith PC (2008) Pharmacokinetics and metabolic profile of free, conjugated, and total silymarin flavonolignans in human plasma after oral administration of milk thistle extract. Drug Metab Dispos 36(1):65–72